“Maximizing Accrual To Transplant Trials In Multiple Myeloma (Mm): Lessons From The Blood And Marrow Transplant Clinical Trials Network (Bmt Ctn), Eastern Cooperative Oncology Group (Ecog) And Cancer And Leukemia Group B (Calgb) Collaboration (Poster).”. In Nci Asco Cancer Trials Accrual Symposium. Nci Asco Cancer Trials Accrual Symposium. Bethesda, MD.
. 2010. “A Phase Ii Study Of Allogeneic Transplantation For Older Patients With Aml In First Complete Remission Using A Reduced Intensity Conditioning Regimen: Results From Calgb 100103/bmt Ctn 0502”. In 54Th Annual Ash Meeting. 54Th Annual Ash Meeting. Atlanta, GA. http://www.hematology.org/Meetings/Annual-Meeting/.
. 2012. “Blood And Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation”. Biol Blood Marrow Transplant 11. Biol Blood Marrow Transplant: 571-575. http://www.ncbi.nlm.nih.gov/pubmed/16041306.
. 2005. “Randomized, Double-Blind, Placebo-Controlled Trial Of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) For The Treatment Of Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation: Bmt Ctn Protocol”. Biol Blood Marrow Transplant 20. Biol Blood Marrow Transplant: 858-864. http://www.ncbi.nlm.nih.gov/pubmed/24607553.
. 2014.